These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 32966993)

  • 1. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
    Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
    Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
    Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
    Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Treatment in Pancreatic Cancer.
    Oba A; Ho F; Bao QR; Al-Musawi MH; Schulick RD; Del Chiaro M
    Front Oncol; 2020; 10():245. PubMed ID: 32185128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
    Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
    Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy.
    Dallavalle S; Campagnoli G; Pastena P; Martinino A; Schiliró D; Giovinazzo F
    Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives.
    Boggi U; Kauffmann EF; Napoli N; Barreto SG; Besselink MG; Fusai GK; Hackert T; Hilal MA; Marchegiani G; Salvia R; Shrikhande SV; Truty M; Werner J; Wolfgang C; Bannone E; Capretti G; Cattelani A; Coppola A; Cucchetti A; De Sio D; Di Dato A; Di Meo G; Fiorillo C; Gianfaldoni C; Ginesini M; Hidalgo Salinas C; Lai Q; Miccoli M; Montorsi R; Pagnanelli M; Poli A; Ricci C; Sucameli F; Tamburrino D; Viti V; Cameron J; Clavien PA; Asbun HJ;
    Updates Surg; 2024 Sep; 76(5):1573-1591. PubMed ID: 38684573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Ferrone CR
    Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
    Lof S; Korrel M; van Hilst J; Alseidi A; Balzano G; Boggi U; Butturini G; Casadei R; Dokmak S; Edwin B; Falconi M; Keck T; Malleo G; de Pastena M; Tomazic A; Wilmink H; Zerbi A; Besselink MG; Abu Hilal M;
    Ann Surg Oncol; 2020 Jun; 27(6):1986-1996. PubMed ID: 31848815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease.
    Kamarajah SK; Chatzizacharias N; Hodson J; Marcon F; Kalisvaart M; Punia P; Ting Ma Y; Dasari B; Marudanayagam R; Sutcliffe RP; Muiesan P; Mirza DF; Isaac J; Roberts KJ
    ANZ J Surg; 2021 Jul; 91(7-8):1549-1557. PubMed ID: 33576568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
    Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
    Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront Surgery and Surgery Following Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: A Comparative Analysis of Short-term Postoperative Outcomes.
    Jung JH; Yoon SK; Yoon SJ; Shin SH; Han IW; Heo JS
    Anticancer Res; 2021 Nov; 41(11):5703-5712. PubMed ID: 34732443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis.
    Rieser CJ; Narayanan S; Bahary N; Bartlett DL; Lee KK; Paniccia A; Smith K; Zureikat AH
    J Surg Oncol; 2021 Oct; 124(5):801-809. PubMed ID: 34231222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.